Seastar Medical Holding Corporation (ICU)
NASDAQ (CM) NASDAQ (CM) Primary 
ASX 
SeaStar Medical Holding Corporation (ICU) Q1 2026 Earnings Call Transcript
SeaStar Medical Holding Corporation (ICU) Q1 2026 Earnings Call Transcript
Implied Volatility Surging for ICU Medical Stock Options
Investors need to pay close attention to ICUI stock based on the movements in the options market lately.
Ondine Biomedical shares rise 8% as ICU study shows nasal photodisinfection cuts pneumonia rates by nearly 40%
A peer-reviewed pilot study at a Canadian critical care centre marks the first deployment of nasal photodisinfection in an intensive care setting. Ondine Biomedical Inc (AIM:OBI, OTC:OBIMF) shares rose 8% to 11.85p after the company announced a peer-reviewed publication of a pilot study showing its Steriwave nasal photodisinfection therapy reduced pneumonia rates by 39.5% in intensive care unit patients.
ICU Medical Moving Toward A Cleaner Margin Leverage And Capital Return Story
ICU Medical is positioned for margin expansion as Smiths Medical integration and remediation costs subside, with upcoming product launches supporting growth. ICUI is gaining share in infusion pumps and consumables, leveraging product differentiation and rebounding from past compliance issues. Management targets net debt/EBITDA below 2.0x, opening the door for increased capital returns via buybacks or dividends within a couple of years.
"Fiat in ICU": Mark Thornton on the silver supply crisis & 2026 crash signals
Jeremy Szafron joins Kitco News as an anchor and producer from Kitco's Vancouver bureau. Jeremy is a seasoned journalist with a diverse background covering entertainment, current affairs and finance.
ICU Medical: Difficult Transition, A More Interesting Company (Upgrade)
ICU Medical has emerged from a painful post-Smiths Medical integration process, shifting focus from remediation to growth and margin expansion. Essentially divesting the low-margin IV solutions business to Otsuka and launching new products can drive gross margin improvement toward 43%-45%. ICUI should achieve sustained EBITDA margins above 20% and double-digit FCF growth, supporting deleveraging and potential capital returns.
Ondine Biomedical shares rise as ICU study shows strong infection-control results
Shares in Ondine Biomedical Inc (AIM:OBI, OTC:OBIMF) climbed 4% to 13p, extending their year-to-date gain to 44%, after the company reported encouraging results from its Steriwave ICU Pilot Study at Royal Columbian Hospital in Canada. The study showed that Steriwave, Ondine's non-antibiotic nasal photodisinfection treatment, significantly reduced harmful pathogens in intensive care patients.
SeaStar Medical Holding Corporation (ICU) Q1 2025 Earnings Call Transcript
SeaStar Medical Holding Corporation (NASDAQ:ICU ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants Jackie Cossmon - IR; WheelHouse Life Science Advisors Eric Schlorff - CEO Tim Varacek - SVP, Commercial & Business Operations; Kevin Chung - Chief Medical Officer David Green - CFO Conference Call Participants Nick Sherwood - Maxim Group Operator Hello and thank you for standing by. My name is Tiffaney and I will be your conference operator today.
ICU Medical's Stock Rises Despite Bivona Tracheostomy Tube Recall
ICUI's Smiths Medical recalls Bivona tracheostomy tubes over a defect that may lead to serious health risks, including airway loss and death.
The Schall Law Firm Invites Investor Participation In A Securities Fraud Case Against SeaStar Medical Holding Corporation
LOS ANGELES, CA / ACCESSWIRE / September 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against SeaStar Medical Holding Corporation ("SeaStar" or "the Company") (NASDAQ:ICU) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 31, 2022 and March 26, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 6, 2024.
SeaStar Medical Holding Corporation Is Being Sued For Violating Securities Regulations And Stockholders Are Invited To Help The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / September 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against SeaStar Medical Holding Corporation ("SeaStar" or "the Company") (NASDAQ:ICU) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 31, 2022 and March 26, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 6, 2024.
The Schall Law Firm Urges Investors To Take Part In A Securities Fraud Case Against SeaStar Medical Holding Corporation
LOS ANGELES, CA / ACCESSWIRE / September 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against SeaStar Medical Holding Corporation ("SeaStar" or "the Company") (NASDAQ:ICU) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 31, 2022 and March 26, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 6, 2024.
